There was exciting news at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, with data from the Hokusai venous thromboembolism (VTE)-Cancer Study (NCT02073682) presented as a late-breaking abstract. Here, Harry Buller, MD, PhD, of the Academic Medical Centre, Amsterdam, Netherlands, discusses whether oral edoxoban could become the new standard of care for cancer-associated VTE. Prof. Buller also shares his predictions on the future of VTE treatment following the success of the Hokusai VTE-Cancer Study.
Next steps in VTE treatment: will oral edoxoban replace the current standard of care?
